Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes

Area of Science:

• Hepatology
• Diabetology
• Biomarker Research

Background:

• Nonalcoholic fatty liver disease (NAFLD) is a growing global health concern.
• Accurate detection of advanced liver fibrosis is crucial for NAFLD management.
• The influence of type 2 diabetes on the diagnostic performance of noninvasive tests (NITs) for NAFLD fibrosis requires further investigation.

Purpose of the Study:

• To compare the diagnostic accuracy of four NITs for advanced fibrosis in NAFLD patients with and without type 2 diabetes.
• To identify the most reliable NIT for detecting advanced fibrosis in NAFLD, particularly in the presence of diabetes.

Main Methods:

• A cohort of 874 biopsy-proven NAFLD patients was analyzed.
• Propensity-score matching was used to create comparable groups of patients with and without diabetes (n=311 each).
• Diagnostic accuracy of FIB-4 index, NAFLD fibrosis score (NFS), APRI, and type IV collagen 7S (COL4-7S) was evaluated using ROC analysis.

Main Results:

• In patients without diabetes, AUROCs ranged from 0.851 (NFS) to 0.883 (COL4-7S).
• In patients with diabetes, AUROCs ranged from 0.771 (APRI) to 0.872 (COL4-7S).
• COL4-7S demonstrated significantly higher diagnostic accuracy than other NITs in NAFLD patients with diabetes.

Conclusions:

• Type IV collagen 7S (COL4-7S) measurement appears to be the most effective noninvasive test for identifying advanced fibrosis in NAFLD.
• COL4-7S shows particular utility in patients with NAFLD and co-existing type 2 diabetes.